PT  - JOURNAL ARTICLE
AU  - Gordon, Debra
TI  - The Future of Antidiabetic Drug Development: GPR40-Selective Agonist TAK-875
DP  - 2010 Dec 01
TA  - MD Conference Express
PG  - 35--36
VI  - 10
IP  - 9
4099  - http://mdc.sagepub.com/content/10/9/35.short
4100  - http://mdc.sagepub.com/content/10/9/35.full
AB  - GPR40 is a G-protein-coupled receptor that is highly expressed in pancreatic β-cells and is involved in free fatty acid-induced insulin secretion. TAK-875 is a GPR40-selective agonist that improves glucose control in type 2 diabetic animal models by stimulating glucose-dependent insulin secretion.